|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM386428344 |
| 003 |
DE-627 |
| 005 |
20250714100624.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
250508s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202419209
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1410.xml
|
| 035 |
|
|
|a (DE-627)NLM386428344
|
| 035 |
|
|
|a (NLM)40166821
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Qian, Siyuan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Synchronous Sterilization and Immunoreaction Termination for Corneal Transparency Protection in Treating Pseudomonas aeruginosa Induced Bacterial Keratitis
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.05.2025
|
| 500 |
|
|
|a Date Revised 19.05.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2025 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a In the treatment of infectious keratitis, therapeutic strategies often prioritize enhancing bactericidal efficacy. However, endotoxins released from Gram-negative bacteria cause inflammatory reaction, leading to corneal structural damage and scar formation. Given that polymyxin B (PMB) can bind and neutralize lipopolysaccharide (LPS), this study employs large-pore mesoporous silica nanoparticles (lMSNs) grafted with PMB as carriers for cationic antibacterial carbon quantum dots (CQDs) to prepare CQDlMSN-PMB, which enables synchronous sterilization and endotoxin neutralization. In the acidic infectious microenvironment, the accelerated release of CQDs eliminates 99.88% bacteria within 2 h, effectively substituting immune mediated sterilization. Notably, CQD@lMSN-PMB exhibits exceptional LPS neutralization performance (2.22 µg LPS/mg CQD@lMSN-PMB) due to its high specific surface area. In an infectious keratitis model, inflammation subsides significantly within the first day of CQD@lMSN-PMB intervention and is completely resolved by day 3. By day 2, interleukin-1β, interleukin-6 and tumor necrosis factor-α in CQD@lMSN-PMB group decrease by 86.99%, 91.15%, and 77.56%, respectively, compared to the CQDs-only sterilization group. Ultimately, corneal integrity and transparency are preserved, with suppressed expressions of fibrosis-related factors including matrix metalloproteinase 9, transforming growth factor-β and α-smooth muscle actin. Therefore, this synchronous sterilization and endotoxin neutralization strategy outperforms monotherapy strategies focused solely on sterilization or endotoxin neutralization
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a endotoxin neutralization
|
| 650 |
|
4 |
|a infectious keratitis
|
| 650 |
|
4 |
|a lipopolysaccharide
|
| 650 |
|
4 |
|a proinflammatory cytokines
|
| 650 |
|
4 |
|a sterilization
|
| 650 |
|
7 |
|a Polymyxin B
|2 NLM
|
| 650 |
|
7 |
|a J2VZ07J96K
|2 NLM
|
| 650 |
|
7 |
|a Anti-Bacterial Agents
|2 NLM
|
| 650 |
|
7 |
|a Silicon Dioxide
|2 NLM
|
| 650 |
|
7 |
|a 7631-86-9
|2 NLM
|
| 650 |
|
7 |
|a Lipopolysaccharides
|2 NLM
|
| 650 |
|
7 |
|a Carbon
|2 NLM
|
| 650 |
|
7 |
|a 7440-44-0
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 700 |
1 |
|
|a Wang, Xuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Yishun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a He, Wenfang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Jianhua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Hao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Renlong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Lili
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xinyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shao, Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Bailiang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 37(2025), 20 vom: 01. Mai, Seite e2419209
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:37
|g year:2025
|g number:20
|g day:01
|g month:05
|g pages:e2419209
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202419209
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 37
|j 2025
|e 20
|b 01
|c 05
|h e2419209
|